GLP-1受体激动剂在心脏移植后糖尿病管理中的疗效与安全性:来自西班牙多中心研究的启示

Efficacy and Safety of GLP-1 Receptor Agonists in Managing Post-Transplant Diabetes Among Heart Transplant Patients: Insights from a Multicenter Spanish Study

This multicenter retrospective study shows that GLP-1 receptor agonists improve glycemic control and cardiometabolic parameters with good tolerance in heart transplant recipients with type 2 diabetes, supporting their therapeutic role in this high-risk population.
Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes

Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes

GLP-1 receptor agonists are increasingly used in women of reproductive age, but their safety during periconception and pregnancy remains unclear. Current observational data show no definitive harm, yet robust evidence is lacking, emphasizing individualized counseling and further research.
Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study

Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study

A French nationwide cohort study finds first-trimester exposure to second-line glucose-lowering agents, including GLP-1 receptor agonists, is generally safe for pregnancies with type 2 diabetes, though a slight increase in cardiac malformations cannot be excluded.
Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches

Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches

This study investigates postoperative complication rates following body-contouring surgery among patients with differing weight-loss methods, revealing that weight-loss modality does not affect complications, while BMI and diabetes at surgery are key predictors.
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophrenia. Semaglutide shows particular promise in improving cardiometabolic health.
GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

GLP-1 Receptor Agonists May Reduce Hospital Admissions for Alcohol and Substance Use Disorders: Insights from a Swedish Nationwide Study

This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of therapy for alcohol use disorder.
Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study

Crowded Optic Discs and Risk Stratification of NAION in GLP-1 Receptor Agonist Users: Insights from a Large Multicenter Study

This large multicenter study reveals that nonarteritic anterior ischemic optic neuropathy (NAION) patients exposed to GLP-1 receptor agonists exhibit similar optic disc crowding compared to nonexposed patients, with smaller cup-to-disc ratios strongly correlating with increased NAION risk.
Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

Evaluating the Risk of Anterior Ischemic Optic Neuropathy with GLP-1 Receptor Agonists in Type 2 Diabetes: Insights from a Swedish Nationwide Cohort Study

A large Swedish cohort study assesses whether glucagon-like peptide-1 receptor agonists increase the risk of anterior ischemic optic neuropathy in type 2 diabetes. Although a borderline elevated relative risk was observed, absolute incidence remained low and confounding factors likely influenced results.
GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among older men with cardiovascular or eye conditions.